RRM
2012 Rustbelt RNA Meeting
RRM
|
|
|
|
|
|
Poster abstracts
Abstract:
Recent advances in pharmacogenomics indicate the importance of RNA in the modulation of pharmacogenetic therapeutic outcomes. RNA provides an effective and critical insight into the understanding of pharmacodynamics of several prominent drug targets in various human disorders. Genome-wide association studies of SNPs, mRNA expression, and trait mapping, reveal the role of regulatory polymorphisms in several mRNA processes such as splicing, transport, stability and translation. Despite the significant role that genes often play in affecting the course of a disease and the treatment outcome, the nature and extent of genetic variability have been inadequately explored. The finding that has come out of the human genome project is the importance of the non-coding region that encodes miRNAs that are predicted to regulate one-third of the human genome, can be used to help predict drug response. Cumulating evidence now demonstrates that non-coding RNA levels in the cell can be a principal determinant of drug sensitivity or resistance, and may serve as biomarkers to assess the associated risk factor.
Our approach is to integrate RNA biology techniques to study the global transcriptome changes of pharmacological relevance in physiologically relevant human autopsy brain tissues by using Next-generation sequencing. Through 'Expression Genetics in Drug Therapy' program at the Department of Pharmacology of the Ohio State University, we aim to fill an important gap, through a systematic study of gene regulation of drug metabolizing enzymes and receptors. This would eventually pave a way into personalized medicine and therapy.
Supported by NIH grant U01 GM092655
Keywords: Transcriptome, pharmacogenomics, non-coding RNA
